Here are three highlights:
1. The patent is for chondrocyte or like cell production to leverage “fibroblasts in vivo with mechanical stress and low oxygen tension.”
2. SpinalCyte is a tissue engineering technology company developing products to re-grow the spinal disc nucleus with human dermal fibroblasts.
3. The company now has 24 U.S. and foreign patents, with 45 pending patents.
More articles on devices:
Relievant Medsystems appoints Kevin Hykes CEO: 4 takeaways
Medovex launches facet joint syndrome relief device in Spain: 5 insights
Implanet reports 19% increase in spine revenue for 1st half of 2017: 7 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
